Hiring
About
Corporate Overview
Founder
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Contact
Videos
CEO Updates
News
Patient Testimonials
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
Platform
Critical Limb Ischemia
News & Media
News / Press Releases
Blog
Investor
Investor Presentations
One Page Overview
Analysts
Public Filings
AGM Materials
MENU ≡
Hiring
About
Corporate Overview
Founder
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Contact
Videos
CEO Updates
News
Patient Testimonials
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
Platform
Critical Limb Ischemia
News & Media
News / Press Releases
Blog
Investor
Investor Presentations
One Page Overview
Analysts
Public Filings
AGM Materials
Contact
Thomas A. Smeenk, BA
President & CEO, Co-Founder
Hemostemix Inc. TSXV:HEM
905-580-4170
tsmeenk@hemostemix.com
Cameron Cole
Head of Investor Relations
Hemostemix Inc. TSXV:HEM
714-520-1185
ccole@hemostemix.com